- Home
- DGNX vs ADPT Comparison
DGNX vs ADPT Comparison
Compare DGNX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGNX
- ADPT
- Stock Information
- Founded
- DGNX 2018
- ADPT 2009
- Country
- DGNX United Kingdom
- ADPT United States
- Employees
- DGNX N/A
- ADPT N/A
- Industry
- DGNX
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DGNX
- ADPT Health Care
- Exchange
- DGNX NYSE
- ADPT Nasdaq
- Market Cap
- DGNX 1.2B
- ADPT 1.4B
- IPO Year
- DGNX 2025
- ADPT 2019
- Fundamental
- Price
- DGNX $47.21
- ADPT $9.53
- Analyst Decision
- DGNX
- ADPT Buy
- Analyst Count
- DGNX 0
- ADPT 6
- Target Price
- DGNX N/A
- ADPT $9.83
- AVG Volume (30 Days)
- DGNX 49.3K
- ADPT 2.5M
- Earning Date
- DGNX 01-01-0001
- ADPT 05-01-2025
- Dividend Yield
- DGNX N/A
- ADPT N/A
- EPS Growth
- DGNX N/A
- ADPT N/A
- EPS
- DGNX N/A
- ADPT N/A
- Revenue
- DGNX $1,177,066.00
- ADPT $189,527,000.00
- Revenue This Year
- DGNX N/A
- ADPT $25.00
- Revenue Next Year
- DGNX N/A
- ADPT $20.38
- P/E Ratio
- DGNX N/A
- ADPT N/A
- Revenue Growth
- DGNX N/A
- ADPT 8.61
- 52 Week Low
- DGNX $3.60
- ADPT $2.99
- 52 Week High
- DGNX $155.00
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- DGNX N/A
- ADPT 59.79
- Support Level
- DGNX N/A
- ADPT $8.50
- Resistance Level
- DGNX N/A
- ADPT $9.69
- Average True Range (ATR)
- DGNX 0.00
- ADPT 0.41
- MACD
- DGNX 0.00
- ADPT -0.01
- Stochastic Oscillator
- DGNX 0.00
- ADPT 77.52
About DGNX DIGINEX LIMITED
Diginex Ltd is an investment holding company. It engaged in providing Environmental, Social, and Governance (ESG) reporting solution services, advisory services, and developing customization solutions.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).